Alfred Bach is responsible for strategic and business development of the company’s group as well as for the research and development. Dr. Bach studied biology in Heidelberg and obtained his doctorate in Heidelberg and San Francisco. He started his professional career as head of CNS research at BASF AG. Before his appointment to the Board of SYGNIS Pharma AG, he acted as Chief Executive Officer of Axaron Bioscience AG, which was specialised in the development of drugs for the central nervous system. Dr. Bach is involved with various committees and associations in the biotechnology industry.
Peter Willinger is responsible for the company’s finances, capital market measures, investor relations, HR management, mergers & acquisitions and corporate investments. He studied business management at the Vocational Academy in Mannheim. Peter Willinger started his career as controller at Rudolf Wild GmbH & Co KG in Heidelberg and later moved to LION bioscience AG. There, he was involved in its IPO and several of the company's capital increases. In November 2004, he was appointed as Board member of LION. In this role, he was responsible for the company’s successful restructuring and realignment and in particular for the sale of the bio-informatics division as well as for the acquisition of SYGNIS Bioscience GmbH & Co. KG.
Frank Rathgeb is responsible for the planning process and management of clinical and regulatory drug development. Moreover, he leads the selection and management of cooperation partners in the development process, as well as the analysis of clinical in-licensing opportunities. Dr. Rathgeb studied medicine at the Universities of Hohenheim and Freiburg. He holds board certifications in anaesthesiology and intensive care medicine as well as clinical pharmacology. Prior to joining SYGNIS in April 2008 he worked for Altana Pharma. Dr. Rathgeb has over 18 years of experience in drug development which includes the development of drug candidates from preclinical stages through to US and EU regulatory approval.
Dietrich Stephan is a founder of Amnestix and Navigenics. He has been the Deputy Director for Discovery Research of The Translational Genomics Research Institute (TGen), Director of the Neurogenomics Division of TGen, Senior Investigator within the Institute. Dr. Stephan is also Chairman of the federally-funded NIH Neuroscience Microarray Consortium, a group of genome centers which provides molecular scanning technology and expertise to a user base of 10,000 scientists across the country. He trained as a human geneticist who has been working to identify the molecular bases of disease for the last 15 years. His work has led to the identification of the genetic bases of dozens of disorders using technologies developed through the Human Genome Project to holistically scan through the molecular makeup of individuals to understand the fundamental differences that can then be targeted for knowledge-based therapeutic development. Dr. Stephan did his undergraduate work at Carnegie Mellon University and his doctoral work in Human Genetics. Thereafter, he trained as a fellow at the National Human Genome Research Institute of the National Institute of Health. Dr. Stephan holds faculty positions at a number of universities across the country, has published extensively in the scientific literature, and serves on numerous scientific advisory boards.
Karoly Nikolich, CEO Amnestix
